CDEK
← All drugs Report issue

chidamide

Small moleculeexperimental

Tucidinostat is a histone deacetylase inhibitor (HDI) developed in China. It was also known as HBI-8000. It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10. — Wikipedia

Clinical trial activity

217 trials · 77 clinical orgs · 0 marketing orgs

Phase 1
43
Phase 2
185
Phase 3
19
Phase 4
4

Earliest trial started Apr 1, 2013 (NCT01836679)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1
Mol. weight
390.42 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • c5055
  • chidamide
  • chidamide
  • chidamide
  • chidamide
  • chidamide
  • cs-055
  • epidaza
  • epidaza
  • epidaza
  • hbi-8000
  • hbi-8000
  • hbi-8000
  • n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07139353Phase 1/Phase 2 (Phase 2)Sep 15, 2025Sun Yat-Sen University
NCT07133763Phase 1/Phase 2 (Phase 2)Sep 1, 2025Xuzhou Medical University
NCT07159620Phase 2Sep 1, 2025Soochow University
NCT07133776Phase 1/Phase 2 (Phase 2)Sep 1, 2025Xuzhou Medical University
NCT07304232Phase 2Sep 1, 2025China Academy of Chinese Medical Sciences
NCT07168317Phase 2Aug 1, 2025Xuzhou Medical University
NCT07081607Phase 2Jul 15, 2025Jiao Tong University
NCT06890585Phase 2Jun 1, 2025Sun Yat-Sen University
NCT06951997Phase 2May 15, 2025Tianjin Medical University
NCT06930118Phase 2Apr 10, 2025Second Military Medical University
NCT07058103Phase 2Apr 1, 2025Xuzhou Medical University
NCT06776952Phase 3Feb 4, 2025Government of China
NCT06745193Phase 2Feb 1, 2025Peking University
NCT06764017Phase 2Feb 1, 2025Ningbo University
NCT06979908Phase 2Jan 22, 2025Jinlin University
NCT06750991Phase 2Dec 31, 2024Jiao Tong University
NCT06671717N/ADec 31, 2024Huazhong University of Science and Technology, Jiao Tong University, Peking University, Sichuan University
NCT06757387Phase 1/Phase 2 (Phase 2)Dec 30, 2024Peking University
NCT06750848Phase 2Dec 20, 2024Chinese Academy of Medical Sciences, Shantou University Medical College
NCT06701357Phase 2Nov 25, 2024Jiao Tong University
Showing 20 of 217 trials
Page 1 / 11

Organizations

Research & Development (77)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Sun Yat-Sen UniversityAcademic/Hospital352732016
People's Liberation Army of ChinaGovernment252142015
Chinese Academy of Medical SciencesAcademic/Hospital221942013
Jiao Tong UniversityAcademic/Hospital191532015
Chipscreen Biosciences, Ltd.For profit14932013
Nanjing Medical UniversityAcademic/Hospital14932016
Soochow UniversityAcademic/Hospital121222017
Peking UniversityAcademic/Hospital11732016
Fudan UniversityAcademic/Hospital9912017
Sichuan UniversityAcademic/Hospital9632017
Southern Medical UniversityAcademic/Hospital8622016
Tianjin Medical UniversityAcademic/Hospital8732016
HUYA Bioscience InternationalFor profit7732014
Fujian Medical UniversityAcademic/Hospital6112021
Xiamen UniversityAcademic/Hospital6412021
Zhengzhou UniversityAcademic/Hospital6522016
Huazhong University of Science and TechnologyAcademic/Hospital5222023
Huizhou People's Central HospitalAcademic/Hospital5012022
Jinlin UniversityAcademic/Hospital5312020
Qingdao UniversityAcademic/Hospital5112017
77 organizations
Page 1 / 4